Fas expression in primary breast cancer is related to neoplastic infiltration of perilymphatic fat

被引:10
作者
Bebenek, M. [1 ]
Dus, D. [2 ]
Kozlak, J. [2 ]
机构
[1] Reg Comprehens Canc Ctr, Dept Surg Oncol 1, PL-53413 Wroclaw, Poland
[2] Polish Acad Sci, Inst Immunol & Expt Therapy, Wroclaw, Poland
来源
ADVANCES IN MEDICAL SCIENCES | 2008年 / 53卷 / 01期
关键词
Fas; Fas-ligand; breast cancer; perilymphatic fat; prognosis;
D O I
10.2478/v10039-008-0015-y
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Purpose: Various studies have revealed that both Fas and its ligand play an important role in cancer biology. The aim of our study was to determine if there is a relationship between the expression of Fas or Fas-ligand in breast cancer and the presence of malignant cells in perilymphatic fat. Material/Methods: Tumor samples from 147 consecutive breast cancer patients, aged 35-81 (median, 59), were subjected to analysis. The expressions of Fas and Fas-ligand were determined immunohistochemically. Results: The expression of Fas, but not Fas-ligand, was significantly less frequent in breast cancer patients in whom malignant cells infiltrated through the perilymphatic fat (p=0.042). The infiltration of paranodal fatty tissue occurred more often in cases of ductal carcinomas (p=0.008), larger primary tumors (pT >= 2, p=0.030) and regional lymph node involvement (pN >= 1, p=0.021). Univariate analysis revealed that perilymphatic fat infiltration shortened overall survivals in breast cancer patients (p=0.05), similarly to postmenopausal status (p=0.034), age >60 years (p=0.05) and regional lymph node involvement (p=0.05). None of the aforementioned factors, however, was revealed as an independent predictor of survival in multivariate analysis. Conclusions: The study showed that lack of Fas in primary breast cancer is associated with perilymphatic fat infiltration. Consequently, both the absence of Fas in the primary tumor and the occurrence of neoplatic cells in paranodal fatty tissue should be considered in the prognosis, complementing existing conventional factors.
引用
收藏
页码:49 / 53
页数:5
相关论文
共 21 条
[1]  
Bebenek M, 2007, ANTICANCER RES, V27, P215
[2]  
Bebenek M, 2006, MED SCI MONITOR, V12, pCR457
[3]   Fas (CD95/APO-1) and Fas ligand expression in normal pancreas and pancreatic tumors - Implications for immune privilege and immune escape [J].
Bernstorff, WV ;
Glickman, JN ;
Odze, RD ;
Farraye, FA ;
Joo, HG ;
Goedegebuure, PS ;
Eberlein, TJ .
CANCER, 2002, 94 (10) :2552-2560
[4]   Altered expression of FAS system is related to adverse clinical outcome in stage I-II breast cancer patients treated with adjuvant anthracycline-based chemotherapy [J].
Botti, C ;
Buglioni, S ;
Benevolo, M ;
Giannarelli, D ;
Papaldo, P ;
Cognetti, F ;
Vici, P ;
Di Filippo, F ;
Del Nonno, F ;
Venanzi, FM ;
Natali, PG ;
Mottolese, M .
CLINICAL CANCER RESEARCH, 2004, 10 (04) :1360-1365
[5]   Sodium butyrate induces P53-independent, Fas-mediated apoptosis in MCF-7 human breast cancer cells [J].
Chopin, V ;
Toillon, RA ;
Jouy, N ;
Le Bourhis, X .
BRITISH JOURNAL OF PHARMACOLOGY, 2002, 135 (01) :79-86
[6]   Prognostic and predictive factors in early-stage breast cancer [J].
Cianfrocca, M ;
Goldstein, LJ .
ONCOLOGIST, 2004, 9 (06) :606-616
[7]   PARANODAL TUMOR IN BREAST-CANCER - EXTRANODAL EXTENSION VERSUS VASCULAR SPREAD [J].
HARTVEIT, F .
JOURNAL OF PATHOLOGY, 1984, 144 (04) :253-256
[8]   Essential requirement for caspase-8/FLICE in the initiation of the Fas-induced apoptotic cascade [J].
Juo, P ;
Kuo, CJ ;
Yuan, JY ;
Blenis, J .
CURRENT BIOLOGY, 1998, 8 (18) :1001-1008
[9]   EXPRESSION OF APO-1 (CD95), A MEMBER OF THE NGF/TNF RECEPTOR SUPERFAMILY, IN NORMAL AND NEOPLASTIC COLON EPITHELIUM [J].
MOLLER, P ;
KORETZ, K ;
LEITHAUSER, F ;
BRUDERLEIN, S ;
HENNE, C ;
QUENTMEIER, A ;
KRAMMER, PH .
INTERNATIONAL JOURNAL OF CANCER, 1994, 57 (03) :371-377
[10]  
Mottolese M, 2000, INT J CANCER, V89, P127, DOI 10.1002/(SICI)1097-0215(20000320)89:2<127::AID-IJC5>3.0.CO